Background: The study aimed to investigate the effects of the active ingredient, nimodipine,
on chondrocyte proliferation and extracellular matrix (ECM) structures in cartilage tissue cells.
Methods: Chondrocyte cultures were prepared from tissues resected via surgical operations. Nimodipine
was then applied to these cultures and molecular analysis was performed. The data obtained were
Results: Both, the results of the (3-(4,5 dimethylthiazol2-yl)-2,5-diphenyltetrazolium (MTT) assay and
the fluorescence microscope analysis [a membrane permeability test carried out with acridine orange/
propidium iodide staining (AO/PI)] confirmed that the active ingredient, nimodipine, negatively
affects the cell cultures.
Conclusion: Nimodipine was reported to suppress cellular proliferation; chondroadherin (CHAD) and
hypoxia-inducible factor-1 alpha (HIF-1α) expression thus decreased by 2.4 and 1.7 times, respectively,
at 24 hrs when compared to the control group (p < 0.05). Furthermore, type II collagen
(COL2A1) expression was not detected (p < 0.05). The risk that a drug prescribed by a clinician in an
innocuous manner to treat a patient by relieving the symptoms of a disease may affect the proliferation,
differentiation, and viability of other cells and/or tissues at the molecular level, beyond its known side
effects or adverse events, should not be forgotten.